Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Department of Pediatrics, University of Toronto, Toronto, ON, Canada.
Eur J Hum Genet. 2024 Nov;32(11):1474-1482. doi: 10.1038/s41431-024-01674-z. Epub 2024 Aug 8.
Rhabdoid tumor predisposition syndrome type-1 (RTPS1) is characterized by germline pathogenic variants in SMARCB1 and development of INI1-deficient rhabdoid tumors in early childhood. Due to its poor prognosis, the risk of subsequent tumor development and the impact of surveillance at later ages are poorly understood. We retrospectively reviewed individuals referred to the Cancer Genetics Program at The Hospital for Sick Children for SMARCB1 genetic testing and/or surveillance for RTPS1. In addition, to explore characteristics of late-onset tumors in RTPS1, a literature review was conducted. Of eighty-three individuals (55 probands and 28 family members), 12 probands and 4 family members were genetically confirmed with RTPS1. Four pediatric probands with RTPS1 underwent surveillance. An additional three individuals, including one patient with 22q11.2 distal deletion without history of tumor, one patient with negative genetic testing results but clinically diagnosed with RTPS1, and one sibling identified through cascade testing, underwent surveillance. Three patients with RTPS1 developed tumors between the ages of 9 and 17, including malignant rhabdoid tumors (N = 3), schwannomas (N = 4), and epithelioid malignant peripheral nerve sheath tumor (N = 1). Three of these lesions were asymptomatically detected by surveillance. A literature review revealed 17 individuals with RTPS1 who developed INI1-deficient tumors after age five. Individuals with RTPS1 remain at elevated risk for developing INI1-deficient tumors after the peak age of rhabdoid tumor in early childhood. Extension of surveillance beyond 5 years of age could lead to improved survival and reduced morbidity for these patients, and prospective evaluation of revised approaches will be important.
横纹肌瘤病易感性综合征 1 型(RTPS1)的特征是存在胚系致病性 SMARCB1 变异,并在儿童早期发生 INI1 缺陷性横纹肌瘤。由于其预后不良,对后续肿瘤发展的风险以及对晚年监测的影响知之甚少。我们对因 SMARCB1 基因检测和/或 RTPS1 监测而转诊至 SickKids 癌症遗传学计划的个体进行了回顾性研究。此外,为了探讨 RTPS1 中迟发性肿瘤的特征,我们进行了文献回顾。在 83 名个体(55 名先证者和 28 名家庭成员)中,12 名先证者和 4 名家庭成员的遗传结果证实患有 RTPS1。4 名患有 RTPS1 的儿科先证者接受了监测。另外 3 名个体,包括 1 名无肿瘤病史的 22q11.2 远端缺失患者、1 名遗传检测结果阴性但临床诊断为 RTPS1 的患者和 1 名通过级联检测发现的同胞,也接受了监测。3 名 RTPS1 患者在 9 至 17 岁之间发生了肿瘤,包括恶性横纹肌瘤(N=3)、神经鞘瘤(N=4)和上皮样恶性外周神经鞘瘤(N=1)。其中 3 个病变是通过监测无症状发现的。文献回顾发现,17 名患有 RTPS1 的个体在 5 岁后发生了 INI1 缺陷性肿瘤。RTPS1 患者在儿童早期横纹肌瘤发病高峰年龄之后仍存在发生 INI1 缺陷性肿瘤的高风险。延长监测时间超过 5 年可能会改善这些患者的生存和降低发病率,对修订方法的前瞻性评估将很重要。